

Robin Cornelissen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449365/publications.pdf>

Version: 2024-02-01

37
papers

771
citations

623188

14
h-index

552369

26
g-index

37
all docs

37
docs citations

37
times ranked

1174
citing authors

#	ARTICLE	IF	CITATIONS
1	Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma. PLoS ONE, 2014, 9, e106742.	1.1	79
2	Pozotinib in Non-HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. Journal of Clinical Oncology, 2022, 40, 710-718.	0.8	72
3	Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human. Clinical Cancer Research, 2018, 24, 766-776.	3.2	68
4	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. European Journal of Cancer, 2021, 144, 41-48.	1.3	64
5	Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. International Journal of Molecular Sciences, 2018, 19, 1041.	1.8	53
6	A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENDritic cell Immunotherapy for Mesothelioma (DENIM) trial. Translational Lung Cancer Research, 2019, 8, 280-285.	1.3	46
7	Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. Journal of Thoracic Oncology, 2020, 15, 1472-1483.	0.5	32
8	Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. OncoImmunology, 2018, 7, e1474318.	2.1	30
9	Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. Translational Lung Cancer Research, 2020, 9, 1169-1179.	1.3	30
10	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889.	0.8	30
11	Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. Radiation Oncology, 2007, 2, 2.	1.2	29
12	A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients. Analytical and Bioanalytical Chemistry, 2010, 398, 2943-2948.	1.9	27
13	Intratumoral macrophage phenotype and CD8 + T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. Lung Cancer, 2015, 88, 332-337.	0.9	22
14	T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma. , 2020, 8, e000251.		19
15	Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients. Lung Cancer, 2017, 107, 36-40.	0.9	18
16	Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis. Frontiers in Oncology, 2020, 10, 577696.	1.3	15
17	Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. Vaccines, 2021, 9, 525.	2.1	13
18	Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response. EBioMedicine, 2021, 64, 103160.	2.7	13

#	ARTICLE	IF	CITATIONS
19	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. <i>Immunotherapy</i> , 2017, 9, 507-520.	1.0	12
20	Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. <i>Thorax</i> , 2022, 77, 1260-1267.	2.7	11
21	Dendritic cell-based immunotherapy in mesothelioma. <i>Immunotherapy</i> , 2012, 4, 1011-1022.	1.0	10
22	Is immunotherapy a viable option in treating mesothelioma?. <i>Future Oncology</i> , 2017, 13, 1747-1750.	1.1	10
23	Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3329-3338.	1.3	10
24	Endovascular Coils as Lung Tumor Fiducial Markers for Real-Time Tumor Tracking in Stereotactic Body Radiotherapy: Comparison of Complication Rates with Transthoracic Fiducial Marker Placement. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1901-1907.	0.2	7
25	Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer. <i>Radiation Oncology</i> , 2020, 15, 89.	1.2	7
26	The psychosocial impact of living with mesothelioma: Experiences and needs of patients and their carers regarding supportive care. <i>European Journal of Cancer Care</i> , 2021, 30, e13498.	0.7	7
27	ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype. <i>Lung Cancer</i> , 2021, 156, 72-75.	0.9	6
28	Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 511-519.	2.1	5
29	Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3074-3074.	0.8	5
30	Biomarkers in malignant mesothelioma – an unfulfilled need or a waste of resources?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1084-S1087.	0.6	4
31	Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1317-1324.	2.0	4
32	Genetic polymorphism in <i>ATIC</i> is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. <i>Thorax</i> , 2021, 76, 1150-1153.	2.7	4
33	Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma. <i>European Journal of Cancer</i> , 2022, 172, 357-366.	1.3	4
34	Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100155.	0.6	3
35	ALK in Mesothelioma: To FISH or Not to FISH?. <i>Journal of Thoracic Oncology</i> , 2020, 15, e168-e169.	0.5	2
36	Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2618-2618.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma. , 2020, 2020, .		0